Filtered By:
Specialty: Pathology
Drug: Docetaxel
This page shows you your search results in order of date.
Order by Relevance | Date
Total 76 results found since Jan 2013.
The oncogenic protein kinase/ATPase RIOK1 is up-regulated via the MYC/E2F transcription factor axis in prostate cancer
In this study, we examined the expression, regulation and therapeutic potential of RIOK1 in PCa. RIOK1 mRNA and protein expression were elevated in PCa tissue samples and correlated with proliferative and protein homeostasis related pathways. RIOK1 was identified as a downstream target gene of the MYC/E2F transcription factors. RIOK1 knock-down and over-expression of the dominant-negative RIOK1-D324A mutant significantly reduced proliferation of PCa cells. Biochemical inhibition of RIOK1 with toyocamycin led to strong anti-proliferative effects in AR-negative and -positive PCa cell lines with EC50 values from 3.5 to 8.8 nM...
Source: The American Journal of Pathology - June 10, 2023 Category: Pathology Authors: Florian Handle Martin Puhr Martina Gruber Chiara Andolfi Georg Sch äfer Helmut Klocker Johannes Haybaeck Peter De Wulf Zoran Culig Source Type: research
miR-194-3p represses the docetaxel resistance in colon cancer by targeting KLK10
Pathol Res Pract. 2022 May 28;236:153962. doi: 10.1016/j.prp.2022.153962. Online ahead of print.ABSTRACTBACKGROUND: Docetaxel (DCT) is widely adopted in chemotherapy for colon cancer (CC). However, DCT resistance can cause chemotherapy failure in CC. MicroRNAs (miRNAs) are key regulators of DCT resistance. Among them, miR-194-3p is a key tumor suppressor, but how it regulates DCT resistance has not been reported yet. This research explored the molecular mechanism of miR-194-3p/Kallikrein Related Peptidase 10 (KLK10) axis in regulating DCT resistance in CC.METHODS: The expression and targeting relationship of miR-194-3p and...
Source: Pathology, Research and Practice - June 12, 2022 Category: Pathology Authors: Jinlai Zhao Yigang Wang Yang Wang Jianchao Gao Xiaotang Wu Hua Li Source Type: research
Selective and marked blockade of endothelial sprouting behavior using paclitaxel and related pharmacologic agents
Am J Pathol. 2021 Sep 23:S0002-9440(21)00393-X. doi: 10.1016/j.ajpath.2021.08.017. Online ahead of print.ABSTRACTHere, we investigate whether alterations in the microtubule cytoskeleton affect the ability of ECs to sprout and form branching networks of tubes. Using defined bioassays of human EC tubulogenesis, where both sprouting behavior and lumen formation can be rigorously evaluated, we demonstrate that addition of the microtubule stabilizing drugs, paclitaxel, docetaxel, ixabepilone, and epothilone B completely interfere with EC tip cells and sprouting behavior, while allowing for EC lumen formation. In bioassays mimic...
Source: The American Journal of Pathology - September 26, 2021 Category: Pathology Authors: Prisca K Lin Jocelynda Salvador Jun Xie Kalia N Aguera Gretchen M Koller Scott S Kemp Courtney T Griffin George E Davis Source Type: research
